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Abstract
Background: Accurate assessment of myocardium at risk (MaR) after acute myocardial infarction (AMI) is necessary
when assessing myocardial salvage. Contrast-enhanced steady-state free precession (CE-SSFP) is a recently developed
cardiovascular magnetic resonance (CMR) method for assessment of MaR up to 1 week after AMI. Our aim was to
validate CE-SSFP for determination of MaR in an experimental porcine model using myocardial perfusion single-photon
emission computed tomography (MPS) as a reference standard and to test the stability of MaR-quantification over time
after injecting gadolinium-based contrast.
Methods: Eleven pigs were subjected to either 35 or 40 min occlusion of the left anterior descending artery followed
by six hours of reperfusion. A technetium-based perfusion tracer was administered intravenously ten minutes before
reperfusion. In-vivo and ex-vivo CE-SSFP CMR was performed followed by ex-vivo MPS imaging. MaR was expressed as
% of left ventricular mass (LVM).
Results: There was good agreement between MaR by ex-vivo CMR and MaR by MPS (bias: 1 ± 3% LVM, r2 = 0.92,
p < 0.001), between ex-vivo and in-vivo CMR (bias 0 ± 2% LVM, r2 = 0.94, p < 0.001) and between in-vivo CMR and MPS
(bias -2 ± 3% LVM, r2 = 0.87, p < 0.001. No change in MaR was seen over the first 30 min after contrast injection (p = 0.95).
Conclusions: Contrast-enhanced SSFP cine CMR can be used to measure MaR, both in vivo and ex vivo, in a porcine
model with good accuracy and precision over the first 30 min after contrast injection. This offers the option to use the
less complex ex-vivo imaging when determining myocardial salvage in experimental studies.
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Background
Treatment options for acute myocardial infarction
(AMI) have steadily increased over the recent decades.
Experimental models have been instrumental to this
since they offer a controlled environment where treat-
ment effects can be developed and assessed prior to pa-
tient trials. An important endpoint for such models is
myocardial salvage and myocardial salvage index (MSI)
[1], used to quantify treatment efficacy. Myocardial
salvage is defined as myocardium at risk (MaR) minus
infarct size and MSI is defined as myocardial salvage
divided by MaR.
Cardiovascular magnetic resonance (CMR) is consid-
ered the reference standard for determining infarct size
in vivo using late gadolinium enhancement (LGE)
imaging typically performed 15–20 min after contrast
administration [2, 3]. Furthermore, CMR has been
shown to enable assessment of MaR using T2-weighted
(T2w) imaging which has been validated both in an ex-
perimental AMI model [4] and in patients up to 1 week
after AMI [5]. However, T2w imaging performs incon-
sistently depending on vendor [6] and on the particular
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implementation of the T2w pulse sequence. Also, T2w
imaging has been shown to be prone to artefacts [7, 8].
Another CMR method for MaR quantification is
contrast-enhanced steady state free precession (CE-
SSFP), which is based on standard SSFP cine images
acquired after contrast injection(9). Since SSFP cine
imaging performs consistently for all vendors and since
images are included in the majority of standard CMR
protocols for assessment of cardiac function, CE-SSFP
can be implemented across centers and does not add to
the total scanning time [6]. CE-SSFP has been validated
in patients with myocardial perfusion single-photon
emission computed tomography (MPS) [9], compared
head-to-head with T2w imaging [10] and used in two
multinational cardio-protection trials, CHILL-MI and
MITOCARE [11, 12]. However, to date CE-SSFP has not
been validated experimentally.
The specific aims for this study were: A. To determine
whether CE-SSFP could be used for determining MaR in
an ex-vivo setting, which would be advantageous for
designing cardioprotective studies where performing
complex in-vivo CMR is not possible. B. To test if the
findings in patients with respect to quantification of
MaR with CE-SSFP would also hold in an in-vivo animal
model and C. To determine whether the timing of
imaging after contrast agent administration affects the
quantification of MaR in vivo.
Methods
Experimental model
The study was approved by the local Ethics Committee
for animal experiments. Pigs (weighing 40–50 kg) were
pre-medicated with ketamine 15 mg/kg (Ketaminol,
Intervet, Danderyd, Sweden) and midazolam 0.5 mg/kg
intramuscularly (Dormicum, Roche AB, Stockholm,
Sweden) after overnight fasting with free access to water.
Anesthesia was induced with propofol 20 mg/ml (Propo-
fol Sandoz A S, Copenhagen, Denmark) and the animals
were intubated using cuffed endotracheal tubes.
Anesthesia was maintained with inhalation of sevoflur-
ane gas (Sevorane, Baxter Medical AB, Kista, Sweden)
using a disposable administration system (AnaConDa,
Sedana Medical AB, Uppsala, Sweden) and titrating to
desired effect. Mechanical ventilation was established
using a 900C ventilator (Siemens AB, Upplands Väsby,
Sweden) in volume controlled mode regulated to a
pCO2 of 5.0–6.0 kPa. Monitoring included arterial blood
pressure, heart rate, ECG, pulse-oximetry and
temperature. Arterial blood gases were drawn and ana-
lyzed directly after establishing arterial access, before
occlusion, after reperfusion, and to follow up any unex-
pected deviation of the blood gas results or change in
the clinical condition of the animal. Venous and arterial
femoral access, jugular access and carotid access were
established using 6–8Fr introducer sheaths. After estab-
lishing all accesses, 20,000 IU of heparin (LEO Pharma
AB, Malmö Sweden) was administered intravenously
and 5% glucose (Baxter Medical AB, Kista, Sweden) was
slowly infused. During the experiments amiodarone
(Sanofi AB, Stockholm, Sweden), fentanyl (50 mikrog/
ml, B. Braun Medical AB, Danderyd, Sweden) and so-
dium chloride (0.9% Baxter Medical AB, Kista, Sweden)
was titrated to desired effect.
Experimental protocol
Pigs were subjected to either 35 or 40-min of left
anterior descending (LAD)-occlusion using a balloon-
tipped catheter, followed by six hours of reperfusion.
The balloon occluder was placed either after the first
or the second diagonal branch of the LAD to obtain
a wide range of MaR. An angiogram was acquired
after inflation of the balloon and before deflation in
order to confirm occlusion of the coronary vessel and
correct balloon placement. Isotope (1000 MBq 99mTc
tetrofosmine) for MPS imaging was administered ten
minutes prior to reperfusion. After deflation of the
balloon a subsequent angiogram was performed to
verify restoration of blood flow. After reperfusion, an-
imals were transported to the MR department.
CMR
In vivo
Imaging was performed on a 1.5 T MR scanner (Phi-
lips Achieva, Best, Netherlands) using a 32-channel
cardiac coil. During in-vivo imaging 0.2 mmol/kg
gadolinium (Gd) based contrast agent (Gd-DOTA)
(Dotarem, Guerbet, Roissy, France) was administrated
intravenously 15 min before LGE-CMR. Using a
retrospectively gated SSFP single slice sequence, a
midventricular short-axis slice of the left ventricle
(LV) was repeatedly acquired during the first ten mi-
nutes after contrast injection. Then, a short-axis
stack covering the entire LV was acquired, using the
same sequence parameters as for the single slice
(typical parameters: TE 1.40 ms, TR 2.8 ms, flip
angle 60°, 25 phases, slice thickness 8 mm, no slice
gap, acquisition matrix 230 x 230, reconstructed
matrix 240 x 240, FOV 320 x 320 mm, pixel band-
width 860 Hz/pixel). LGE images were acquired 15–
20 min after contrast injection using an inversion re-
covery gradient echo sequence (typical parameters:
TE 3.0, TR 6.1 ms, TI 320 ms, slice thickness 8 mm,
no slice gap, acquisition matrix 200 x 158, recon-
structed matrix 510 x 510, FOV 320 x 320 mm, pixel
bandwidth 260 Hz/pixel).
After CE-SSFP and LGE imaging an additional single
slice of SSFP in the same position as above was acquired
20–30 min after contrast injection. Both CE-SSFP and
Nordlund et al. Journal of Cardiovascular Magnetic Resonance  (2017) 19:12 Page 2 of 8
LGE slices were obtained during end-expiratory breath
hold. Long axis 2-, 3 and 4-chamber views using both
CE-SSFP and LGE were also acquired. Fifteen minutes
before euthanization an additional 0.2 mmol/kg Gd-
DOTA was administrated. Pigs were euthanized with a
rapid infusion of saturated potassium chloride solution
and the hearts were explanted and suspended in plastic
containers with deuterated water-filled balloons in the
ventricles for ex-vivo imaging.
Ex vivo
ex-vivo CMR was performed on the same scanner as
above, using a simulated ECG with heart rate 60 beats per
minute for triggering. A full coverage LV short-axis stack
was acquired using the same settings as for the in-vivo se-
quence above (typical parameters: TE 1.40 ms, TR 2.8 ms,
flip angle 60°, 25 phases, slice thickness 8 mm, no slice
gap, acquisition matrix 60 x 50, reconstructed matrix 80 x
80, FOV 100 × 100 mm, pixel bandwidth 1400 Hz/pixel).
A high resolution T1-weighted short axis stack was ac-
quired for detailed infarct visualization (TE 3.4 ms, TR
20 ms, 0.5 mm isotropic voxels, no slice gap, acquisition
matrix 200 × 200, reconstructed matrix 220 × 220, FOV
100 × 100 mm, pixel bandwidth 440 Hz/pixel).
MPS
ex-vivo MPS was performed approximately 8–10 h after
intravenous injection of a 1000 MBq dose of 99mTc-
tetrofosmin using a dual head camera (Philips SKYlight,
Best, the Netherlands) and a vertex high resolution colli-
mator (ADAC Vertex, Milpitas, CA, USA) at 32 projec-
tions (40 s per projection) with a 64 × 64 matrix yielding
a digital resolution of 4.24 mm isotropic voxels. Iterative
reconstruction using maximum likelihood expectation
maximization (MLEM) was performed with a low reso-
lution Butterworth filter with a cut-off frequency set to
0.6 of Nyquist and order 5.0. No attenuation or scatter
correction was applied. Finally, a short-axis image stack
was reconstructed using commercially available software
(AutoSPECT Plus, Pegasys software version 5.01, Philips,
Best, The Netherlands).
Image analysis
All images were analyzed using the software Segment,
version 1.9 R3314 (http://segment.heiberg.se) [13]. MaR
from the in-vivo CE-SSFP images was assessed according
to a previously described method [9]. In short, LVM was
defined by manual delineation of the epicardial and
endocardial borders in end-diastolic and end-systolic
timeframes. Hyperintense myocardium was then manu-
ally delineated and defined as MaR. The same method
was used to delineate MaR in ex-vivo CE-SSFP images.
The analysis of CE-SSFP images was performed both by
a blinded primary observer and an independent, blinded
secondary observer. When delineating CE-SSFP images
over time after injection of gadolinium all images were
sorted randomly both between timepoints and between
experiments and observers were blinded to the
randomization.
Infarcted myocardium was delineated from the in-vivo
short-axis LGE images according to a previously defined
method [14]. In short, the endocardial and epicardial
borders were manually traced with exclusion of the pap-
illary muscles. The LGE myocardium was defined using
a computer algorithm that takes into consideration par-
tial volume effects within the infarcted region [14].
Manual adjustments were made when image artefacts
caused misinterpretation by the computer algorithm.
Hypointense signal within the area of LGE, microvascu-
lar obstruction [15], was included and considered as
infarction.
The high resolution T1-weighted ex-vivo images were
also delineated according to a previously described and
validated method [16]. In short, the endocardial and
epicardial borders were traced manually including the
papillary muscles. Infarct was defined as >8 standard de-
viations from a manually defined remote region. Manual
adjustments were made if the computer algorithm was
clearly wrong due to image artefacts or inclusion of
intramyocardial fat as infarct.
MaR and infarct size was expressed as percentage of
LVM. Myocardial salvage index (MSI) was calculated as
(MaR-infarct size)/MaR =MSI.
Evaluation of MPS images was performed by using
anatomical information from the high resolution T1-
weighted ex-vivo images and perfusion information from
MPS according to a previously described method [17].
In short, both T1-weighted and MPS images were re-
sampled to similar resolutions and were spatially
matched using purpose-designed software. Delineations
of endocardium and epicardium from the T1-weighted
images were then used for defining the myocardium in
the MPS images. MaR was then automatically defined by
calculating and applying a threshold and performing
manual adjustments as previously described [17].
Statistics
Analyses were performed using GraphPad Prism (ver-
sion 6.00, GraphPad Software, San Diego, USA) or IBM
SPSS Statistics (version 23, IBM Corporation, New York,
USA). Results for continuous variables are expressed as
mean ± standard deviation. Bias according to Bland-
Altman was used to compare MaR by MPS, in-vivo CE-
SSFP and ex-vivo CE-SSFP. Bias according to Bland Alt-
man was also used to compare MaR by MPS, in-vivo
CE-SSFP and ex-vivo CE-SSFP to infarct size by LGE
imaging [18], and for inter-observer analysis. A paired t-
test was used to test ex-vivo CE-SSFP vs MPS and in-
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vivo CE-SSFP vs ex-vivo CE-SSFP. Pearson correlation
coefficient was used for assessment of correlation between
ex-vivo CE-SSFP, MPS, in-vivo CE-SSFP, infarct, and for
inter-observer analysis. When comparing MaR over time
for the single-slice images, the MaR was normalized to
MaR of the first acquired slice. Subsequently a repeated
measures linear mixed model using time as a nominal vari-
able and a fixed effect was used to test for differences in
MaR between different time points after contrast injection.
P < 0.05 indicated statistical significance.
Results
Study population
Twelve pigs were included in the study. In one pig
no infarct or MaR could be identified neither with in-
vivo or ex-vivo CMR nor with MPS. In two pigs the
in-vivo images were considered of non-diagnostic quality
due to severe arrhythmias and high heart rate (>120 bpm).
MPS images were of diagnostic quality in all pigs.
MaR
Images of MaR by ex-vivo CE-SSFP and MPS from
one pig of typical quality is shown in Fig. 1. A good
correlation with a low bias was found between MaR
by ex-vivo CE-SSFP (29 ± 9%) and MPS (30 ± 9%) (n =
11, bias: 1 ± 3%, r2 = 0.92, p < 0.001, Fig. 2). There was
also a good correlation with a low bias between MaR
by in-vivo CE-SSFP (31 ± 8%) and ex-vivo CE-SSFP (n
= 9, bias: 0 ± 2%, r2 = 0.94, p < 0.001, Fig. 2). MaR by
in-vivo CE-SSFP vs MPS showed a low bias (-2 ± 3%)
and a good correlation (n = 9, r2 = 0.87, p < 0.001,
Fig. 2). Inter-observer analysis for the ex-vivo CE-
SSFP showed a low bias (n = 11, bias: -1.5 ± 3.7%, r2 =
0.98). For the in-vivo CE-SSFP bias was also low (n =
9, bias: -0.4 ± 4.3%, r2 = 0.77).
Infarct
Examples of infarct- and MaR-images in vivo and ex vivo
of typical quality are seen in Fig. 3. Infarct size was 13 ±
10% by high-resolution T1-weighted ex-vivo imaging. In-
farct size on average was smaller than MaR by MPS,
CE-SSFP ex vivo and CE-SSFP in vivo in all pigs
(mean difference 17 ± 10%, 15 ± 8% and 16 ± 9%
respectively).
Myocardial salvage Index
Myocardial salvage index was 52 ± 28% by ex-vivo CE-
SSFP and high resolution T1-weighted ex-vivo imaging.
MaR over time
Images of MaR over time in one animal are seen in
Fig. 4. On average, the MaR at baseline did not change
over 30 min after contrast injection (p = 0.95). Bias for
different times after contrast injection compared to
baseline is shown in Fig. 5. Inter-observer analysis for
MaR over time showed a low bias (0.9 ± 5.7%, r2 = 0.77).
Discussion
This study validates CE-SSFP in an experimental setting
and shows that this technique can be used to measure
MaR with high accuracy and precision in vivo and ex
vivo. It also shows that CE-SSFP for measurement of
MaR is stable at least up to 30 min after contrast
injection.
Potential mechanisms for detecting MaR with CE-SSFP
The increased signal found in the entire MaR is likely
explained by a shift in the T2/T1 ratio that deter-
mines signal contrast for the balanced SSFP sequence
[19]. Without the contrast agent the tissue edema
results in a higher ratio as T2 seems to be
Fig. 1 Myocardium at risk (MaR) is shown to have similar extent with ex-vivo CE-SSFP (top row) and MPS (bottom row) in matched slices from the
same heart. The green line denotes epicardium, the red line endocardium and the white line MaR. MPS =myocardial perfusion single photon
emission tomography
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proportionally more increased than T1 [20]. At cer-
tain concentrations of contrast agent myocardial T1
may decrease proportionally more than T2, thus fur-
ther increasing the T2/T1 ratio. It has been shown
that the MaR has an increased distribution volume of con-
trast agent compared to remote myocardium [21–23],
which could allow for the contrast agent to affect the T2/
T1 ratio to a greater degree in MaR yielding an observable
difference in signal intensity. Further studies will be
needed to elucidate the mechanisms behind the tissue
contrast between MaR and remote myocardium in CE-
SSFP.
The single-slice data over time shows that CE-SSFP
MaR imaging can be performed from less than 2 min
up to 30 min after contrast agent injection with no
detectable changes in the extent of the MaR. This
suggests a rapidly established equilibrium of contrast
agent between the extracellular compartments (in
blood, remote myocardium, MaR, infarct) in which
the contrast agent is distributed (excepting areas of
microvascular obstruction wherein contrast wash in is
delayed or wholly obstructed). Previous studies have
shown an increase in T1-relaxation times that is
proportional between the extracellular compartments
over 30 min after contrast injection which corrobo-
rates this finding [21, 22, 24, 25].
Previous studies using CE-SSFP for MaR
Sörensson et al. validated CE-SSFP using MPS as reference




Fig. 2 Myocardium at risk (MaR) by MRI and MPS show overall good correlation and agreement. Panel a shows a good correlation between MaR by
ex-vivo CE-SSFP and MaR by myocardial perfusion SPECT (MPS). The corresponding Bland-Altman plot in panel b shows a low bias. Panel c shows a
good correlation between MaR by ex-vivo CE-SSFP and MaR by in-vivo CE-SSFP, with a low bias (panel d). Panel e shows a good correlation between
MaR by in-vivo CE-SSFP and MaR by MPS. The corresponding Bland-Altman plot in panel f shows a low bias. In all cases, MaR is expressed as percent
of left ventricular mass. The dotted lines in a, c and e represent the line of identity
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infarction [9]. They found a bias of 0.5 ± 5.1% with a
correlation of r2 = 0.78. In addition, Ubachs et al.
showed good agreement between T2-STIR and CE-
SSFP for assessment of MaR in a single-center, single-
vendor setting [10]. More recently, CE-SSFP has been
shown to be more robust than T2-STIR in a multi-
center, multi-vendor setting [6]. Furthermore, in ac-
cordance with the findings in the present study that
MaR is constant over time early after contrast injec-
tion, Ubachs et al. showed a constant relationship be-
tween MaR by pre-contrast T2-STIR and CE-SSFP
acquired 2–12 min after contrast injection [10].
Thus, CE-SSFP offers a robust method for determin-
ation of MaR which has made it the method of choice
for several clinical cardioprotection trials [11, 12, 26].
Experimental and clinical implications
MaR has been determined experimentally for several
decades but has required separate modalities such as
histopathology dyes, microspheres, and radioisotope
imaging, making image co-registration a challenge
[4, 21, 22, 27, 28]. Using CE-SSFP to determine MaR
abolishes the need for separate modalities as both
infarct size and MaR can be assessed in one single
CMR session. Thus, co-registration of infarct and
MaR can be performed accurately on a slice-by-slice
basis. Furthermore, CE-SSFP cine imaging enables
assessment of both MaR and myocardial function
which enables calculation of myocardial salvage and
myocardial salvage index and reducing the number
of subjects with preserved power [29]. Since myocar-
dial function is an essential part of most in-vivo pro-
tocols, the use of CE-SSFP shortens the CMR
examination as it abolishes the need for separate
scanning for assessment of MaR and myocardial
function. In addition. The ability to use ex-vivo or
in-vivo CE-SSFP interchangeably confers the option
to perform only ex-vivo scanning and forego the
more complex in-vivo scanning when determining
myocardial salvage in experimental studies.
Fig. 3 Infarct and myocardium at risk (MaR) in vivo and ex vivo. The
upper row shows infarct by late gadolinium enhancement (LGE) and
MaR by CE-SSFP in vivo and the lower row shows infarct by high-
resolution T1-weighted imaging and MaR by CE-SSFP ex vivo. Note
the significantly larger MaR compared to infarction both in vivo and
ex vivo
Fig. 4 Myocardium at risk (MaR) by CE-SSFP at various time points after contrast agent administration. The upper row shows CE-SSFP at the end-diastolic
(ED) time-frame and the bottom row at the end-systolic (ES) time-frame. The green line denotes epicardium, the red line endocardium and the white line
MaR. Note that there is no change in the extent of MaR over time. Note also that there is a hypointense core within MaR at 3 min not visible at later
timepoints. This could be due to slower contrast filling to this area, possibly because of microvascular obstruction
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Limitations
The findings in the present study should be interpreted in
the light of the following limitations. First, when compar-
ing MaR-size over time, single midventricular slices, and
not full LV coverage, were acquired. Thus, the total MaR
was not assessed repeatedly, rather the percentage of MaR
in a single slice. Second, the data over time after contrast-
injection could not be acquired at all timepoints for all
animals. This was due to both technical (e.g. triggering
problems) and medical reasons (e.g. hemodynamic instabil-
ity requiring intervention), interrupting imaging acquisition
in some animals. Third, manual delineation was used to as-
sess MaR. Manual delineation has, however, been validated
against MPS [9]. In future studies, techniques such as T1-
or T2-mapping sequences could potentially allow auto-
matic or semi-automatic evaluation of MaR [20, 30], how-
ever, more standardization and validation is needed before
these techniques can be used in clinical trials.
Conclusion
Contrast-enhanced SSFP cine CMR imaging can be used
to measure MaR, both in vivo and ex vivo, in a porcine
model with good accuracy and precision over the first
30 min after contrast injection. This offers the option to
use the less complex ex-vivo imaging when determining
myocardial salvage in experimental studies.
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